Marco Boorsma

Marco is General Partner at Forbion and joined the team in 2007.

Marco has a key role in the investment team and a special interest to bring his background in molecular biology, operational and business development experience from both small and large businesses to the portfolio, and to establish and manage new companies as part of Forbion’s the build strategy. He currently serves on the boards of Inversago, Escalier Biosciences, and EnGene.

Marco was instrumental in the start-up of Dezima and served on its board until Dezima was acquired by Amgen for up to USD1.5Bn in 2015. Marco also served on the board of Akarna, which was sold to Allergan for up to USD 1Bn in 2016, on the board Prexton Therapeutics that was sold to Lundbeck in 2018 for up to USD 1.1Bn, and on the board of Inflazome that was sold to Roche in 2020 for USD450m and contingent milestone payments. Marco was observer to the board of Exosome Diagnostics that was sold to Bio-Techne for up to USD 575m. He previously served on the board of Replimune ($REPL), RSPR Pharma, NorthSea Therapeutics, Milestone Pharmaceutical ($MIST), and was observer at Oxyrane and Cardoz.